Perimenopause Treatment

Tell the clinician what is happening and what it prevents you from doing. Waking soaked in sweat, needing to change menstrual protection during a meeting, and pain during penetration are different clinical problems. A symptom diary and bleeding record can help establish their frequency and severity.

Systemic estrogen is the most effective treatment for menopause-related hot flashes and night sweats. It reaches the bloodstream in sufficient amounts to act throughout the body. Options include tablets, patches, gels, and sprays. Reducing nighttime heat can also improve sleep when those episodes are causing the waking.

If you have a uterus, systemic estrogen generally needs progesterone or another progestogen to protect the uterine lining from excessive growth and reduce endometrial cancer risk. When periods continue, a clinician may use a cyclical regimen with planned progestogen days and a withdrawal bleed. The schedule should fit your bleeding history.

Before prescribing, the clinician reviews unexplained bleeding, medication, and your personal and family history. A history of breast or endometrial cancer, a blood clot, stroke, heart attack, or liver disease can make systemic treatment unsuitable or call for specialist advice. Estrogen patches may carry a lower blood clot risk than pills, but the whole history still affects the decision.

Side effects can include breast tenderness, bloating, headaches, and spotting. Report persistent or troublesome effects so the dose, route, or progestogen can be reviewed. Ask what bleeding is expected on your prescribed schedule and which changes require investigation.

Pregnancy remains possible during perimenopause. Menopause hormone therapy does not provide contraceptive protection, so discuss pregnancy prevention separately. For eligible women, combined hormonal contraception can make bleeding more predictable and may reduce hot flashes.

A levonorgestrel IUD can reduce heavy menstrual bleeding and provide contraception. Some clinicians use a suitable device alongside estrogen to protect the uterine lining. In the United States, using Mirena for that purpose is off-label. Ask which device is appropriate and when it must be replaced for endometrial protection; the contraceptive duration does not establish its duration for this use.

Heavy bleeding should be assessed before it is attributed to the transition. Fibroids, polyps, pregnancy-related causes, and changes in the uterine lining may need investigation. Depending on the findings, treatment can include hormonal methods, tranexamic acid, or other medication or procedures.

Bring a record of bleeding days, flow, clots, pain, and spotting between periods or after sex. A blood count may be needed to check whether blood loss has caused anemia.

Certain antidepressants, including low-dose paroxetine, can reduce hot flashes. Gabapentin and oxybutynin are also used for selected patients. Some uses are off-label. The clinician should explain the intended benefit, likely side effects, interactions, and whether the medicine could also help or complicate another condition.

Fezolinetant and elinzanetant

Fezolinetant, sold as Veozah, and elinzanetant, sold as Lynkuet, are nonhormonal prescriptions for moderate to severe hot flashes due to menopause. They act on neurokinin receptors involved in temperature regulation. Their monitoring requirements differ.

Veozah can cause rare but serious liver injury. Its prescribing plan includes liver blood tests before treatment, monthly for the first three months, and at months six and nine. If signs of liver injury occur, such as yellow skin or eyes, dark urine, unusual itching, or abdominal pain, stop it and contact the prescriber immediately.

Lynkuet requires liver testing before treatment and at three months. Its current label includes warnings about sleepiness, dizziness, daytime impairment, and seizure risk. It is contraindicated in pregnancy; people who could become pregnant need pregnancy testing and effective contraception during treatment and for two weeks afterward. Discuss the current label with the prescriber before starting.

For persistent insomnia, cognitive behavioral therapy for insomnia, or CBT-I, is usually the first treatment recommended. It addresses sleep timing, time spent awake in bed, and the worry that can develop around sleep. It can be delivered in person or remotely by a trained professional.

Menopause-specific CBT can help with the impact of hot flashes and associated sleep or mild depressive symptoms. A clinician may also assess sleep apnea if you snore, gasp during sleep, or feel persistently unrefreshed.

Anxiety that disrupts everyday life and depression need their own assessment. Talking therapy, medication, or both may be appropriate. Hormone treatment can be discussed for menopause symptoms while those conditions receive care. Seek help promptly if you are struggling to cope.

A vaginal moisturizer is used regularly to ease dryness; a lubricant reduces friction during sex. Persistent burning, dryness, or pain with penetration may respond to low-dose vaginal estrogen, available in several forms. Local treatment can be considered alongside systemic hormone therapy if vaginal symptoms remain.

Tell the clinician about unusual discharge, bleeding, urinary pain, or new soreness so infection and other causes can be considered. If you have a history of breast cancer, discuss vaginal treatment with your care team because the choice depends partly on your cancer treatment and ongoing medication.

• Which symptom the treatment is intended to improve, and how you will judge improvement.
• The dose, route, schedule, and any blood tests required.
• Expected side effects and bleeding, with instructions for contacting the prescriber.
• A review at about three months, then regular follow-up as the symptoms and treatment change.

Ask about supplements before starting them, especially if you take other medication. Product quality, interactions, and evidence vary. Bring the product label to the discussion so the ingredients and dose can be checked.